Nutritional treatment for traumatic brain injury

Journal of Neurotrauma

Volumn 31, Issue 11, 2014, Pages 989-999

  Scrimgeour, Angus G ^a   Condlin, Michelle L ^a  

^a U S ARMY RESEARCH INSTITUTE OF ENVIRONMENTAL MEDICINE   (United States)

Author keywords

glutamine; omega 3; review; traumatic brain injury; vitamin D; zinc

Indexed keywords

ALANINE; ANTIOXIDANT; CALCITRIOL; COLECALCIFEROL; DOCOSAHEXAENOIC ACID; FISH OIL; GLUTAMINE; ICOSAPENTAENOIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PROBIOTIC AGENT; PROGESTERONE; VITAMIN D; ZINC; ZINC SULFATE; VITAMIN;

BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DIET SUPPLEMENTATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EVIDENCE BASED PRACTICE; HUMAN; MAJOR DEPRESSION; MORBIDITY; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; NUTRITIONAL SUPPORT; REVIEW; SIDE EFFECT; TRAUMATIC BRAIN INJURY; VITAMIN D DEFICIENCY; BRAIN INJURIES; DIET THERAPY;

BRAIN INJURIES; FATTY ACIDS, OMEGA-3; GLUTAMINE; HUMANS; NUTRITION THERAPY; VITAMIN D; VITAMINS; ZINC;

EID: 84902009669     PISSN: 08977151     EISSN: 15579042     Source Type: Journal    
DOI: 10.1089/neu.2013.3234     Document Type: Review

References (162)

1. Humphreys, I., Wood, R.L., Phillips, C.J., and Macey, S. (2013). The costs of traumatic brain injury: a literature review. Clinicoecon. Outcomes Res. 5, 281-287.
2. Flanagan, S.R., Cantor, J.B., and Ashman, T.A. Traumatic brain injury: future assessment tools and treatment prospects. (2008). Neuropsychiatr. Dis. Treat. 4, 877-892.
3. Cook, A.M., Peppard, A., and Magnuson, B. (2008). Nutrition considerations in traumatic brain injury. Nutr. Clin. Pract. 23, 608-620.
4. Bistrian, B.R., Askew, W., Erdman, J.W., Jr., and Oria, M.P. (2011). Nutrition and traumatic brain injury: a perspective from the Institute of Medicine report. J. Parenter. Enteral Nutr. 35, 556-559.
5. Wang, X., Dong, Y., Han, X., Qi, X.Q., Huang, C.G., and Hou, L.J. (2013). Nutritional support for patients sustaining traumatic brain injury: a systematic review and meta-analysis of prospective studies. PLoS ONE 8, e58838.
6. Food and Nutrition Board. (2011). Nutrition and Traumatic Brain Injury-Improving Acute and Subacute Health Outcomes in Military Personnel. National Academies Press: Washington, D.C.
7. Bansal, V., Costantini, T., Kroll, L., Peterson, C., Loomis, W., Eliceiri, B., Baird, A., Wolf, P., and Colimbra, R. et al. (2009). Traumatic brain injury and intestinal dysfunction: uncovering the neuro-enteric axis. J. Neurotrauma 26, 1353-1359.
8. Bratton, S.L., Chestnut, R.M., Ghajar, J., McConnell Hammond, F.F., Harris, O.A., Hartl, R., Manley, G.T., Nemecek, A., Newell, D.W., Rosenthal, G., Schouten, J., Shutter, L., Timmons, S.D., Ull-man, J.S., Videtta, W., Wilberger, J.E., and Wright, D.W. (2007). Guidelines for the management of severe traumatic brain injury. XII. Nutrition. J. Neurotrauma 24, Suppl 1, S77-S82.
9. Dobson, K., and Scott, A. (2007). Review of ICU nutrition support practices: implementing the nurse-led enteral feeding algorithm. Nurs. Crit. Care. 12, 114-123.
10. Fertl, E., Steinhoff, N., Schofl, R., et al. (1998). Transient and long-term feeding by means of percutaneous endoscopic gastrostomy in neurological rehabilitation. Eur. Neurol. 40, 27-30.
11. Perel, P., Yanagawa, T., Bunn, F., Roberts, I., Wentz, R., and Pierro, A. (2006). Nutritional support for head-injured patients. Cochrane Database Syst. Rev. CD001530.
12. Rhoney, D.H., and Parker, D., Jr. (2006). Considerations in fluids and electrolytes after traumatic brain injury. Nutr Clin Pract 21, 462-478.
13. Vizzini, A., and Aranda-Michel, J. Nutritional support in head injury. (2011). Nutrition 27, 129-132.
14. Loane, D.J., and Faden, A.I. (2010). Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol. Sci. 31, 596-604.
15. Dyall, S.C., and Michael-Titus, A.T. (2008). Neurological benefits of omega-3 fatty acids. Neuromolecular Med. 10, 219-235.
16. Salem, N., Jr., Litman, B., Kim, H.Y., and Gawrisch, K. (2001). Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 36, 945-959.
17. Cao, D., Xue, R., Xu, J., and Liu, Z. (2005). Effects of docosahex-aenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. J. Nutr. Biochem. 16, 538-546.
18. Robson, L.G., Dyall, S., Sidloff, D., and Michael-Titus, A.T. (2010). Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol. Aging 31, 678-687.
19. Macintosh, B.A., Ramsden, C.E., Faurot, K.R. Zamora, D., Mangan, M., Hibbeln, J.R., and Mann. J.D. (2013). Low-n-6 and low-n-6 plus high-n-3 diets for use in clinical research. Br. J. Nutr. 110, 559-568.
20. Serhan, C.N., and Petasis, N.A. (2011). Resolvins and protectins in inflammation resolution. Chem. Rev. 111, 5922-5943.
21. Kotani, S., Sakaguchi, E., Warashina, S., Matsukawa, N., Ishikura, Y., Kiso, Y., Sakakibara, M., Yoshimoto, T., Guo, J., and Yama-shima, T. (2006). Dietary supplementation of arachidonic and doc-osahexaenoic acids improves cognitive dysfunction. Neurosci. Res. 56, 159-164.
22. Morley, J.E., and Banks, W.A. Lipids and cognition. (2010). J. Alzheimers Dis. 20, 737-747.
23. Simopoulos, A.P. (2011). Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev. Nutr. Diet 102, 10-21.
24. Russo, G.L. (2009). Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. Biochem. Pharmacol. 77, 937-946.
25. LaRosa, J.H. (1988). National Cholesterol Education Program: report of the expert panel on the detection, evaluation, and treatment of high blood cholesterol in adults. J. Occup. Med. 30, 826-829.
26. Calder, P.C. (2011). Fatty acids and inflammation: the cutting edge between food and pharma. Eur. J. Pharmacol. 668, Suppl 1, S50-S58.
27. Youdim, K.A., Martin, A., and Joseph, J.A. (2000). Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neu-rosci. 18, 383-399.
28. Homayoun, P., Parkins, N.E., Soblosky, J., Carey, M.E., Rodriguez de Turco, E.B., and Bazan, N.G. (2000). Cortical impact injury in rats promotes a rapid and sustained increase in polyunsaturated free fatty acids and diacylglycerols. Neurochem. Res. 25, 269-276.
29. Horrocks, L.A., and Farooqui, A.A. (2004). Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot. Essent. Fatty Acids 70, 361-372.
30. Wu, A., Ying, Z., and Gomez-Pinilla, F. (2011). The salutary effects of DHA dietary supplementation on cognition, neuroplasticity, and membrane homeostasis after brain trauma. J. Neurotrauma 28, 2113-2122.
31. Mills, J.D., Bailes, J.E., Sedney, C.L., Hutchins, H., and Sears, B. (2011), Omega-3 fatty acid supplementation and reduction of traumatic axonal injury in a rodent head injury model. J. Neurosurg. 114, 77-84.
32. Mills, J.D., Hadley, K., Bailes, J.E. (2011). Dietary supplementation with the omega-3 fatty acid docosahexaenoic acid in traumatic brain injury. Neurosurgery 68, 474-481.
33. Bailes, J.E., and Mills, J.D. (2010). Docosahexaenoic acid (DHA) reduces traumatic axonal injury in a rodent head injury model. J. Neurotrauma 27, 1617-1624.
34. Lewis, M.D., Hibbeln, J.R., Johnson, J.E., Lin, Y.H., Hyun, D.Y., and Loewke, J.D. (2011). Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. J. Clin. Psychiatry 72, 1585-1590.
35. Hibbeln, J.R. (2009). Depression, suicide and deficiencies of omega-3 essential fatty acids in modern diets. World Rev. Nutr. Diet 99, 17-30.
36. Hanson JA, Haub MD, Walker JJ, Johnston DT, Goff BS, Dretsch MN. (2012). Attention deficit hyperactivity disorder subtypes and their relation to cognitive functioning, mood states, and combat stress symptomatology in deploying U.S. soldiers. Mil. Med. 177, 655-662.
37. von Schacky, C. (2009). Cardiovascular disease prevention and treatment. Prostaglandins Leukot. Essent. Fatty Acids 81, 193-198.
38. Pestka, J.J. (2010). n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis. Prostaglandins Leukot. Essent. Fatty Acids 82, 251-258.
39. Wu, A., Ying, Z., and Gomez-Pinilla, F. (2004). Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma 21, 1457-1467.
40. Wu, A., Ying, Z., and Gomez-Pinilla, F. (2007). Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeo-stasis in traumatic brain injury. J. Neurotrauma 24, 1587-1595.
41. Mayurasakorn, K., Williams, J.J., Ten, V.S., and Deckelbaum, R.J. (2011). Docosahexaenoic acid: brain accretion and roles in neuro-protection after brain hypoxia and ischemia. Curr. Opin. Clin. Nutr. Metab. Care 14, 158-167.
42. Palacios-Pelaez, R., Lukiw, W.J., and Bazan, N.G. (2010). Omega-3 essential fatty acids modulate initiation and progression of neuro-degenerative disease. Mol. Neurobiol. 41, 367-374.
43. Rona, R.J. (2012). Long-term consequences of mild traumatic brain injury. Br. J. Psychiatry 201, 172-174.
44. Hogyes, E., Nyakas, C., Kiliaan, A., Farkas, T., Penke, B., and Luiten, P.G. (2003). Neuroprotective effect of developmental doc-osahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 119, 999-1012.
45. Cao, D.H., Xu, J.F., Xue, R.H., Zheng, W.F., and Liu, Z.L. (2004). Protective effect of chronic ethyl docosahexaenoate administration on brain injury in ischemic gerbils. Pharmacol. Biochem. Behav. 79, 651-659.
46. Calderon, F., and Kim. H.Y. (2004). Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J. Neurochem. 90, 979-988.
47. Wang, X., Zhao, X., Mao, Z.Y., Wang, X.M., and Liu, Z.L. (2003). Neuroprotective effect of docosahexaenoic acid on glutamate-in-duced cytotoxicity in rat hippocampal cultures. NeuroReport 14, 2457-2461.
48. Hu, F.B., Bronner, L., Willett, W.C., Stampfer, M.J., Rexrode, K.M., Albert, C.M., Hunter, D., and Manson, J.E. (2002). Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 287, 1815-1821.
49. Mozaffarian, D., Longstreth, W.T., Jr., Lemaitre, R.N., Manolio, T.A., Kuller, L.H., Burke, G.L., and Siscovick, D.S. (2005). Fish consumption and stroke risk in elderly individuals: the cardiovascular health study. Arch. Intern. Med. 165, 200-206.
50. Tanaka, K., Ishikawa, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Saito, Y., Matsuzawa, Y., Sasaki, J., Oikawa, S., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shi-mada, K., and Shirato, K.; JELIS Investigators, Japan (2008). Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 39, 2052-2058.
51. Yoneda, H., Shirao, S., Kurokawa, T., Fujisawa, H., Kato, S., and Suzuki, M. (2008). Does eicosapentaenoic acid (EPA) inhibit cerebral vasospasm in patients after aneurysmal subarachnoid hemorrhage? Acta Neurol. Scand. 118, 54-59.
52. Poppitt, S.D., Howe, C.A., Lithander, F.E., Silvers, K.M., Lin, R.B., Croft, J., Ratnasabapathy, Y., Gibson, R.A., and Anderson, C.S. (2009). Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke 40, 3485-3492.
53. Bromfield, E., Dworetzky, B., Hurwitz, S., Eluri, Z., Lane, L., Replansky, S,. and Mostofsky, D. (2008). A randomized trial of polyunsaturated fatty acids for refractory epilepsy. Epilepsy Behav. 12, 187-190.
54. Puri, B.K., Koepp, M.J., Holmes, J., Hamilton, G., and Yuen, A.W. (2007). A 31-phosphorus neurospectroscopy study of omega-3 long-chain polyunsaturated fatty acid intervention with eicosapentaenoic acid and docosahexaenoic acid in patients with chronic refractory epilepsy. Prostaglandins Leukot. Essent. Fatty Acids 77, 105-107.
55. Davidson, M.H., Stein, E.A., Bays, H.E., Maki, K.C., Doyle, R.T., Shalwitz, R.A., Ballantyne, C.M., and Ginsberg, H.N; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. (2007). Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 29, 1354-1367.
56. Wohl, D.A., Tien, H.C., Busby, M., Cunningham, C., Macintosh, B., Napravnik, S., Danan, E., Donovan, K., Hossenipour, M., and Simpson, R.J., Jr. (2005). Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin. Infect. Dis. 41, 1498-1504.
57. Ott, J., Hiesgen, C., and Mayer, K. (2011). Lipids in critical care medicine. Prostaglandins Leukot. Essent. Fatty Acids 85, 267-273.
58. Rapoport, S.I., Rao, J.S., and Igarashi, M. (2007). Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot. Essent. Fatty Acids 77, 251-261.
59. Substances affirmed as generally recognized as safe: Menhaden oil. (1997). Final Rule: Federal Registry 30751-30757.
60. Harris, W.S., Kris-Etherton, P.M., and Harris, K.A. (2008). Intakes of long-chain omega-3 fatty acid associated with reduced risk for death from coronary heart disease in healthy adults. Curr. Atheroscler. Rep. 10, 503-509.
61. Lien, E.L. (2009). Toxicology and safety of DHA. Prostaglandins Leukot. Essent. Fatty Acids 81, 125-132.
62. Pedersen, H.S., Mulvad, G., Seidelin, K.N., Malcom, G.T., and Boudreau, D.A. (1999). N-3 fatty acids as a risk factor for haemor-rhagic stroke. Lancet 353, 812-813.
63. Maresta, A., Balduccelli, M., Varani, E., Marzilli, M., Galli, C., Heiman, F., Lavezzari, M., Stragliotto, E., and De Caterina, R.; ESPRIT Investigators. et al. (2002). Prevention of postcoronary an-gioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT). Am. Heart. J. 143, E5.
64. Filion, K.B., El Khoury, F., Bielinski, M., Schiller, I., Dendukuri, N., and Brophy, J.M. (2010). Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord. 10, 24.
65. Marik, P.E., and Varon, J. (2009). Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin. Cardiol. 32, 365-372.
66. Woodman, R.J., Mori, T.A., Burke, V., Puddey, I.B., Barden, A., Watts, G.F., and Beilin, L.J. (2003). Effects of purified eicosa-pentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 166, 85-93.
67. Kris-Etherton, P.M., Harris, W.S., and Appel, L.J. (2003). Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 23, 151-152.
68. Bays, H.E. (2007). Safety considerations with omega-3 fatty acid therapy. Am. J. Cardiol. 99, 35C-43C.
69. Calo, L., Bianconi, L., Colivicchi, F., Lamberti, F., Loricchio, M.L., de Ruvo, E., Meo, A., Pandozi, C., Staibano, M., and Santini, M. (2005). N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J. Am. Coll. Cardiol. 45, 1723-1728.
70. Covington, M.B. (2004). Omega-3 fatty acids. Am. Fam. Physician 70, 133-140.
71. Xiong, Y., Mahmood, A., and Chopp, M. (2009). Emerging treatments for traumatic brain injury. Expert Opin. Emerg. Drugs 14, 67-84.
72. Matthews, L.R., Danner, O.K., Ahmed, Y.A., et al. (2014). Combination therapy with vitamin D3, progesterone, omega-3 fatty acids, and glutamine reverses coma and improves clinical outcomes in patients with severe traumatic brain injuries: a case series. IJCRI 4, 143-149.
73. Cope, E.C., Morris, D.R., and Levenson, C.W. (2012). Improving treatments and outcomes: an emerging role for zinc in traumatic brain injury. Nutr. Rev. 70, 410-413.
74. McClain, C.J., Twyman, D.L., Ott, L.G., Rapp, R.P., Tibbs, P.A., Norton, J.A., Kasarskis, E.J., Dempsey, R.J., and Young, B. (1986). Serum and urine zinc response in head-injured patients. J. Neurosurg. 64, 224-230.
75. McClain, C.J., Hennig, B., Ott, L.G., Goldblum, S., and Young, A.B. (1988). Mechanisms and implications of hypoalbuminemia in head-injured patients. J. Neurosurg. 1988;69, 386-392.
76. Young, A.B., Ott, L.G., Beard, D., Dempsey, R.J., Tibbs, P.A., and McClain, C.J. (1988). The acute-phase response of the brain-injured patient. J. Neurosurg. 69, 375-380.
77. Vasto, S., Mocchegiani, E., Malavolta, M., Cuppari, I., List̀i, F., Nuzzo, D., Ditta, V., Candore, G., and Caruso, C. (2007). Zinc and inflammatory/immune response in aging. Ann. N. Y. Acad. Sci. 1100, 111-122.
78. Young, B., Ott, L., Kasarskis, E., Rapp, R., Moles, K., Dempsey, R.J., Tibbs, P.A., Kryscio, R., and McClain, C. (1996). Zinc supplementation is associated with improved neurologic recovery rate and visceral protein levels of patients with severe closed head injury. J. Neurotrauma 13, 25-34.
79. Gibson, R.S., Hess, S.Y., Hotz, C., and Brown, K.H. (2008). Indicators of zinc status at the population level: a review of the evidence. Br. J. Nutr. 99, Suppl 3, S14-S23.
80. Jorge, R.E., and Starkstein, S.E. (2005). Pathophysiologic aspects of major depression following traumatic brain injury. J. Head Trauma Rehabil. 20, 475-487.
81. Swardfager, W., Herrmann, N., Mazereeuw, G., Goldberger, K., Harimoto, T., and Lanctot, K.L. (2013). Zinc in depression: a meta-analysis. Biol. Psychiatry 74, 872-878.
82. Manser, W.W., Khan, M.A., and Hasan, K.Z. (1989). Trace element studies on Karachi population. Part IV: Blood copper, zinc, magnesium and lead levels in psychiatric patients with depression, mental retardation and seizure disorders. J. Pak. Med. Assoc. 39, 269-274.
83. Szewczyk, B., Kubera, M., and Nowak, G. (2011). The role of zinc in neurodegenerative inflammatory pathways in depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 693-701.
84. Nowak G, Szewczyk B, and Pilc A. (2005). Zinc and depression. An update. Pharmacol. Rep. 57, 713-718.
85. Maes, M., D'Haese, P.C., Scharpe, S., D'Hondt, P., Cosyns, P., and De Broe, M.E. (1994). Hypozincemia in depression. J. Affect. Dis-ord. 31, 135-140.
86. Nowak, G., Zieba, A., Dudek, D., Krooeniak, M., Szymaczek, M., and Schlegel-Zawadzka, M. (1999). Serum trace elements in animal models and human depression. Part I. Zinc. Hum. Psychopharmacol. Clin. Exp. 14, 83-86.
87. Maes, M., Vandoolaeghe, E., Neels, H., Demedts, P., Wauters, A., Meltzer, H.Y., Altamura, C., and Desnyder, R. (1997). Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol. Psychiatry 42, 349-358.
88. McLoughlin, I.J., and Hodge, J.S. (1990). Zinc in depressive disorder. Acta Psychiatr. Scand. 82, 451-453.
89. Lai, J., Moxey, A., Nowak, G., Vashum, K., Bailey, K., and McEvoy, M. (2012). The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J. Affect. Disord. 136, e31-e39.
90. Cope, E.C., Morris, D.R., Scrimgeour, A.G., Vanlandingham, J.W., and Levenson, C.W. (2011). Zinc supplementation provides behavioral resiliency in a rat model of traumatic brain injury. Physiol. Behav. 104, 942-947.
91. Hellmich, H.L., Frederickson, C.J., DeWitt, D.S., Saban, R., Parsley, M.O., Stephenson, R., Velasco, M., Uchida, T., Shimamura, M., and Prough, D.S. (2004). Protective effects of zinc chelation in traumatic brain injury correlate with upregulation of neuroprotective genes in rat brain. Neurosci. Lett. 355, 221-225.
92. Yeiser, E.C., Lerant, A.A., Casto, R.M., and Levenson, C.W. (1999). Free zinc increases at the site of injury after cortical stab wounds in mature but not immature rat brain. Neurosci. Lett. 277, 75-78.
93. Gower-Winter, S.D., and Levenson, C.W. (2012). Zinc in the central nervous system: From molecules to behavior. Biofactors 38, 186-193.
94. McCranor, B.J., Bozym, R.A., Vitolo, M.I., Fierke, C.A., Bambrick, L., Polster, B.M., Fiskum, G., and Thompson, R.B. (2012). Quantitative imaging of mitochondrial and cytosolic free zinc levels in an in vitro model of ischemia/reperfusion. J. Bioenerg. Biomembr. 44, 253-263.
95. Cho, E., Lee, K.J., Seo, J.W., Byun, C.J., Chung, S.J., Suh, D.C., Carmeliet, P., Koh, J.Y., Kim, J.S., and Lee, J.Y. (2012). Neuro-protection by urokinase plasminogen activator in the hippocampus. Neurobiol. Dis. 46, 215-224.
96. Suh, S.W., Chen, J.W., Motamedi, M., Bell, B., Listiak, K., Pons, N.F., Danscher, G., and Frederickson, C.J. (2000). Evidence that synaptically-released zinc contributes to neuronal injury after traumatic brain injury. Brain Res. 852, 268-273.
97. Hellmich, H.L., Eidson, K.A., Capra, B.A., Garcia, J.M., Boone, D.R., Hawkins, B.E., Uchida, T., Dewitt, D.S., Prough, D, S. (2007). Injured fluoro-jade-positive hippocampal neurons contain high levels of zinc after traumatic brain injury. Brain Res. 1127, 119-126.
98. Hellmich, H.L., Eidson, K., Cowart, J., Crookshanks, J., Boone, D.K., Shah, S., Uchida, T., DeWitt, D.S., and Prough, D.S. (2008). Chelation of neurotoxic zinc levels does not improve neurobeha-vioral outcome after traumatic brain injury. Neurosci. Lett. 440, 155-159.
99. Levenson, C.W. (2005). Zinc supplementation: neuroprotective or neurotoxic? Nutr. Rev. 63, 122-125.
100. Yeiser, E.C., Vanlandingham, J.W., and Levenson, C.W. (2002). Moderate zinc deficiency increases cell death after brain injury in the rat. Nutr. Neurosci. 5, 345-352.
101. Shabanzadeh, A.P., Shuaib, A., Yang, T., Salam, A., and Wang, C.X. (2004). Effect of zinc in ischemic brain injury in an embolic model of stroke in rats. Neurosci. Lett. 356, 69-71.
102. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. (2001). Dietary Reference Intakes For Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academy Press: Washington, D.C., pps. 442-501.
103. Wessels, I., Haase, H., Engelhardt, G., Rink, L., and Uciechowski, P. (2013). Zinc deficiency induces production of the proinflammatory cytokines IL-1b and TNFa in promyeloid cells via epigenetic and redox-dependent mechanisms. J. Nutr. Biochem. 24, 289-297.
104. Clausen, F., Marklund, N., Lewen, A., Enblad, P., Basu, S., and Hillered, L. (2012). Interstitial F(2)-isoprostane 8-iso-PGF(2alpha) as a biomarker of oxidative stress after severe human traumatic brain injury. J. Neurotrauma 29, 766-775.
105. Calvo, M.S., Whiting, S.J., Barton, C.N. (2005). Vitamin D intake: a global perspective of current status. J. Nutr. 135, 310-316.
106. Food and Nutrition Board. (2011). Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press: Washington, D.C.
107. Vieth, R., Bischoff-Ferrari, H., Boucher, B.J., Dawson-Hughes, B., Garland, C.F., Heaney, R.P., Holick, M.F., Hollis, B.W., Lamberg-Allardt, C., McGrath, J.J., Norman, A.W., Scragg, R,. Whiting, S.J., Willett, W.C., and Zittermann, A. (2007). The urgent need to recommend an intake of vitamin D that is effective. Am. J. Clin. Nutr. 85, 649-650.
108. Lips, P. (2007). Vitamin D status and nutrition in Europe and Asia. J. Steroid Biochem. Mol. Biol. 103, 620-625.
109. Cekic, M., and Stein, D.G. (2010). Traumatic brain injury and aging: is a combination of progesterone and vitamin D hormone a simple solution to a complex problem? Neurotherapeutics 7, 81-90.
110. Gordon, C.M., DePeter, K.C., Feldman, H.A., Grace, E., and Emans, S.J. (2004). Prevalence of vitamin D deficiency among healthy adolescents. Arch. Pediatr. Adolesc. Med. 158, 531-537.
111. Evatt, M.L., DeLong, M.R., Khazai, N., Rosen, A., Triche, S., and Tangpricha, V. (2008). Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch. Neurol. 65, 1348-1352.
112. Buell, J.S., Dawson-Hughes, B., Scott, T.M., Weiner, D.E., Dallal, G.E., Qui, W.Q., Bergethon, P., Rosenberg, I.H., Folstein, M.F., Patz, S., Bhadelia, R.A., and Tucker, K.L. (2010). 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 74, 18-26.
113. Anderson, J.L., May, H.T., Horne, B.D., Bair, T.L., Hall, N.L., Carlquist, J.F., Lappé, D.L., and Muhlestein, J.B.; Intermountain Heart Collaborative (IHC) Study Group. et al. (2010). Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am. J. Car-diol. 106, 963-968.
114. Pilz, S., Dobnig, H., Fischer, J.E., Wellnitz, B., Seelhorst, U., Boehm, B.O., and März, W. (2008). Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 39, 2611-2613.
115. Hypponen, E., and Boucher, B.J. (2010). Avoidance of vitamin D deficiency in pregnancy in the United Kingdom: the case for a unified approach in National policy. Br. J. Nutr. 104, 309-314.
116. Cekic, M., Cutler, S.M., Vanlandingham, J.W., and Stein, D.G. (2011). Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol. Aging 32, 864-874.
117. Witham, M.D., Dove, F.J., Sugden, J.A., Doney, A.S., and Struthers, A.D. (2012). The effect of vitamin D replacement on markers of vascular health in stroke patients-a randomised controlled trial. Nutr. Metab. Cardiovasc. Dis. 22, 864-870.
118. Atif, F., Sayeed, I., Ishrat, T., and Stein DG. (2009). Progesterone with vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Mol. Med. 15, 328-336.
119. Wright, D.W., Kellermann, A.L., Hertzberg, V.S., Clark, P.L., Frankel, M., Goldstein, F.C., Salomone, J.P., Dent, L.L., Harris, O.A., Ander, D.S., Lowery, D.W., Patel, M.M., Denson, D.D., Gordon, A.B., Wald, M.M., Gupta, S., Hoffman, S.W., and Stein, D.G. (2007). ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 49, 391-402.
120. Xiao, G., Wei, J., Yan, W., Wang, W., and Lu, Z. (2008). Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. Crit. Care 12, R61.
121. Cekic, M., Sayeed, I., and Stein, D.G. (2009). Combination treatment with progesterone and vitamin D hormone may be more effective than monotherapy for nervous system injury and disease. Front. Neuroendocrinol. 30, 158-172.
122. Stein, D.G. (2013). A clinical/translational perspective: can a developmental hormone play a role in the treatment of traumatic brain injury? Horm. Behav. 63, 291-300.
123. Buell, J.S., and Dawson-Hughes, B. (2008). Vitamin D and neuro-cognitive dysfunction: preventing "D"ecline? Mol. Aspects Med. 29, 415-422.
124. Schnieders, J., Willemsen, D., and de Boer, H. (2012). Factors contributing to chronic fatigue after traumatic brain injury. J. Head Trauma Rehabil. 27, 404-412.
125. Chen, T.C., Chimeh, F., Lu, Z., Mathieu, J., Person, K.S., Zhang, A., Kohn, N., Martinello, S., Berkowitz, R., and Holick, M.F. (2007). Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch. Biochem. Biophys. 460, 213-217.
126. Holick, M.F., and Chen, T.C. (2008). Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87, 1080S-1086S.
127. Nagpal, S., Na, S., and Rathnachalam, R. (2005). Noncalcemic actions of vitamin D receptor ligands. Endocr. Rev. 26, 662-687.
128. Aminmansour, B., Nikbakht, H., Ghorbani, A., Rezvani, M., Rah-mani, P., Torkashvand, M., Nourian, M., and Moradi, M. (2012). Comparison of the administration of progesterone versus progesterone and vitamin D in improvement of outcomes in patients with traumatic brain injury: A randomized clinical trial with placebo group. Adv. Biomed. Res. 1, 58.
129. Morse, N.L. (2012). Benefits of docosahexaenoic acid, folic acid, vitamin D and iodine on foetal and infant brain development and function following maternal supplementation during pregnancy and lactation. Nutrients 4, 799-840.
130. van Groningen, L., Opdenoordt, S., van Sorge, A., Telting, D., Giesen, A., and de Boer, H. (2010). Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur. J. Endocrinol. 162, 805-811.
131. Novak, F., Heyland, D.K., Avenell, A., Drover, J.W., and Su, X. (2002). Glutamine supplementation in serious illness: a systematic review of the evidence. Crit. Care Med. 30, 2022-2029.
132. Wernerman, J. (2011). Glutamine supplementation. Ann. Intensive Care 1:25.
133. Wang, W.W., Qiao, S.Y., and Li, D.F. (2009). Amino acids and gut function. Amino Acids 37, 105-110.
134. Li, Y., Li, J., Jiang, J., Li, N., Wang, X., Wang, Z., Wu, B., and Liu, F. (2003). Glycyl-glutamine-supplemented long-term total parenteral nutrition selectively improves structure and function in heterotopic small-bowel autotransplantation in the pig. Transpl. Int. 16, 866-871.
135. Coeffier, M., Marion, R., Leplingard, A., Lerebours, E., Ducrotte, P., and Dechelotte, P. (2002). Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in vitro. Cytokine 18, 92-97.
136. Quan, Z.F., Yang, C., Li, N., and Li, J.S. (2004). Effect of glutamine on change in early postoperative intestinal permeability and its relation to systemic inflammatory response. World J. Gastroenterol. 10, 1992-1994.
137. Arndt, H., Kullmann, F., Reuss, F., Scholmerich, J., and Palitzsch, K.D. (1999). Glutamine attenuates leukocyte-endothelial cell adhesion in indomethacin-induced intestinal inflammation in the rat. J. Parenter. Enteral Nutr. 23, 12-18.
138. Zeng, J., Zhao, X.Y., Huang, Q., and Wang, E.R. (2009). [Effects of glutamine-enriched enteral nutrition on nutritional status and prognosis of patients with severe head injury.] (Chi) Zhonghua Shao Shang Za Zhi 25, 335-338.
139. Falcao de Arruda, I.S., and de Aguilar-Nascimento, J.E. (2004). Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients. Clin. Sci. (Lond) 106, 287-292.
140. Yang, D.L., and Xu, J.F. (2007). Effect of dipeptide of glutamine and alanine on severe traumatic brain injury. Chin. J. Traumatol. 10, 145-149.
141. Lim, Y.H., Kim, D.H., Lee, M.Y., and Joo, M.C. (2012). Bowel dysfunction and colon transit time in brain-injured patients. Ann. Rehabil. Med. 36, 371-378.
142. Chen, G., Shi, J., Qi, M., Yin, H., and Hang, C. (2008). Glutamine decreases intestinal nuclear factor kappa B activity and pro-inflammatory cytokine expression after traumatic brain injury in rats. In-flamm. Res. 57, 57-64.
143. Feng, D., Xu, W., Chen, G., Hang, C., Gao, H., and Yin, H. (2007). Influence of glutamine on intestinal inflammatory response, mucosa structure alterations and apoptosis following traumatic brain injury in rats. J. Int. Med. Res. 35, 644-656.
144. Jones, C., Palmer, T.E., and Griffiths, R.D. (1999). Randomized clinical outcome study of critically ill patients given glutamine-supplemented enteral nutrition. Nutrition 15, 108-115.
145. Griffiths, R.D., Jones, C., and Palmer, T.E. (1997). Six-month outcome of critically ill patients given glutamine-supplemented paren-teral nutrition. Nutrition 13, 295-302.
146. Rodas, P.C., Rooyackers, O., Hebert, C., Norberg, A., and Werner-man, J. (2012). Glutamine and glutathione at ICU admission in relation to outcome. Clin. Sci. (Lond) 122, 591-597.
147. Chen, Q.H., Yang, Y., He, H.L., Xie, J.F., Cai, S.X., Liu, A.R., Wang, H.L., and Qiu, H.B. (2014). The effect of glutamine therapy on outcomes in critically ill patients: a meta-analysis of randomized controlled trials. Crit. Care 18, R8.
148. Heyland, D., Muscedere, J., Wischmeyer, P.E., Cook, D., Jones, G., Albert, M., Elke, G., Berger, M.M., and Day, A.G; Canadian Critical Care Trials Group. (2013). A randomized trial of gluta-mine and antioxidants in critically ill patients. N. Engl. J. Med. 368, 1489-1497.
149. Heyland, D., Wischmeyer, P.E., and Day, A.G. (2013). Glutamine and antioxidants in critically ill patients. N. Engl. J. Med. 369, 484-485.
150. Oudemans-van Straaten, H.M., Bosman, R.J., Treskes, M., van der Spoel, H.J., and Zandstra, D.F. (2001). Plasma glutamine depletion and patient outcome in acute ICU admissions. Intensive Care Med. 27, 84-90.
151. Heyland, D.K., and Dhaliwal, R. (2013). Role of glutamine supplementation in critical illness given the results of the REDOXS study. JPEN 37, 442-443.
152. Newsholme, P., Procopio, J., Lima, M.M., Pithon-Curi, T.C., and Curi, R. (2003). Glutamine and glutamate-their central role in cell metabolism and function. Cell Biochem. Funct. 21, 1-9.
153. Kim, H. Glutamine as an immunonutrient. (2011). Yonsei. Med. J. 52, 892-897.
154. Berg, A., Bellander, B.M., Wanecek, M., Gamrin, L., Elving, A., Rooyackers, O., Ungerstedt, U., and Wernerman, J. (2006). Intravenous glutamine supplementation to head trauma patients leaves cerebral glutamate concentration unaffected. Intensive Care Med. 32, 1741-1746.
155. Goeters, C., Wenn, A, Mertes, N., Wempe, C., Van Aken, H., Stehle, P., Bone, H.G. (2002). Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. Crit. Care Med. 30, 2032-2037.
156. Wernerman, J., Kirketeig, T., Andersson, B., Berthelson, H., Ersson, A., Friberg, H., Guttormsen, A.B., Hendrikx, S., Pettilä, V., Rossi, P., Sjöberg, F., and Winsö, O; Scandinavian Critical Care Trials Group. (2011). Scandinavian glutamine trial: a pragmatic multi-centre randomised clinical trial of intensive care unit patients. Acta Anaes-thesiol. Scand. 55, 812-818.
157. Rooyackers, O., Forsberg, A.M., Vesali, R.F., Garlick, P.J., and Wernerman, J. (2004). Effects on skeletal muscle of intravenous glutamine supplementation to ICU patients. Intensive Care Med. 30, 266-275.
158. Heyland, D.K., and Novak, F. (2001). Immunonutrition in the critically ill patient: more harm than good? JPEN 25, S51-S56.
159. McClave, S.A., Martindale, R.G., Vanek, V.W., McCarthy, M., Roberts, P., Taylor, B., Ochoa, J.B., Napolitano, L., and Cresci, G.; A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine. (2009). Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN 33, 277-316.
160. Zhou, M., and Martindale, R.G. (2007). Arginine in the critical care setting. J. Nutr. 137, Suppl 2, 1687S-1692S.
161. Zuhl, M.N., Lanphere, K.R., Kravitz, L., Mermier, C.M., Schneider, S., Dokladny, K., and Moseley, P.L. (2014). Effects of oral glutamine supplementation on exercise-induced gastrointestinal permeability and tight junction protein expression. J. Appl. Physiol. 2014;116, 183-191.
162. Chourdakis, M., Kraus, M.M., Tzellos, T., Sardeli, C., Peftoulidou, M., Vassilakos, D., and Kouvelas, D. (2012). Effect of early compared with delayed enteral nutrition on endocrine function in patients with traumatic brain injury: an open-labeled randomized trial. JPEN 36, 108-116.